{"height":"190","provider_url":"https://hatena.blog","author_name":"lung-cancer","categories":["\u6cbb\u7642 \u5206\u5b50\u6a19\u7684\u85ac"],"width":"100%","image_url":"https://cdn-ak.f.st-hatena.com/images/fotolife/l/lung-cancer/20200605/20200605094159.png","type":"rich","published":"2020-06-06 06:00:00","title":"\u3010INSIGHT\u3011MET\u904e\u5270\u767a\u73fe/MET\u5897\u5e45+EGFR\u967d\u6027\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u306b\u5bfe\u3059\u308b\u30c6\u30dd\u30c1\u30cb\u30d6+\u30b2\u30d5\u30a3\u30c1\u30cb\u30d6\u306e\u7b2c1b/2\u76f8\u8a66\u9a13","provider_name":"Hatena Blog","description":"\u300eTepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial\u300f\uff08Lancet Respir Med 2020 Published Online May 29,\u2026","author_url":"https://blog.hatena.ne.jp/lung-cancer/","html":"<iframe src=\"https://hatenablog-parts.com/embed?url=https%3A%2F%2Flk.hatenablog.jp%2Fentry%2F2020%2F06%2F06%2F060000\" title=\"\u3010INSIGHT\u3011MET\u904e\u5270\u767a\u73fe/MET\u5897\u5e45+EGFR\u967d\u6027\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u306b\u5bfe\u3059\u308b\u30c6\u30dd\u30c1\u30cb\u30d6+\u30b2\u30d5\u30a3\u30c1\u30cb\u30d6\u306e\u7b2c1b/2\u76f8\u8a66\u9a13 - \u30ad\u30e5\u30fc\u30c8\u5148\u751f\u306e\u300e\u80ba\u764c\u52c9\u5f37\u4f1a\u300f\" class=\"embed-card embed-blogcard\" scrolling=\"no\" frameborder=\"0\" style=\"display: block; width: 100%; height: 190px; max-width: 500px; margin: 10px 0px;\"></iframe>","blog_url":"https://lk.hatenablog.jp/","url":"https://lk.hatenablog.jp/entry/2020/06/06/060000","version":"1.0","blog_title":"\u30ad\u30e5\u30fc\u30c8\u5148\u751f\u306e\u300e\u80ba\u764c\u52c9\u5f37\u4f1a\u300f"}